BRPI0414918A - compostos de benzoimidazola - Google Patents

compostos de benzoimidazola

Info

Publication number
BRPI0414918A
BRPI0414918A BRPI0414918-1A BRPI0414918A BRPI0414918A BR PI0414918 A BRPI0414918 A BR PI0414918A BR PI0414918 A BRPI0414918 A BR PI0414918A BR PI0414918 A BRPI0414918 A BR PI0414918A
Authority
BR
Brazil
Prior art keywords
benzoimidazole compounds
conditions
benzoimidazole
compounds
inflammation
Prior art date
Application number
BRPI0414918-1A
Other languages
English (en)
Inventor
Kristen L Arienti
James Guy Breitenbucher
Daniel J Buzard
James P Edwards
Michael D Hack
Haripada Khatuya
David E Kindrachuk
Alice Lee-Dutra
Jennifer D Venable
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0414918A publication Critical patent/BRPI0414918A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ceramic Engineering (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSTOS DE BENZOIMIDAZOLA". Compostos de benzoimidazol, composições e métodos de uso dos mesmos em inibição do recrutamento de leucócitos, na modulação do receptor de H~ 4~ e no tratamento de condições tais como inflamação, condições H~ 4~-mediadas e condições relacionadas.
BRPI0414918-1A 2003-09-30 2004-09-29 compostos de benzoimidazola BRPI0414918A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50723603P 2003-09-30 2003-09-30
PCT/US2004/031855 WO2005044807A2 (en) 2003-09-30 2004-09-29 Benzoimidazole compounds

Publications (1)

Publication Number Publication Date
BRPI0414918A true BRPI0414918A (pt) 2006-11-07

Family

ID=38952593

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414918-1A BRPI0414918A (pt) 2003-09-30 2004-09-29 compostos de benzoimidazola

Country Status (21)

Country Link
US (10) US7432378B2 (pt)
EP (1) EP1673348B1 (pt)
JP (1) JP2007508011A (pt)
KR (1) KR20060097024A (pt)
CN (1) CN1886380B (pt)
AR (1) AR045955A1 (pt)
AT (1) ATE427303T1 (pt)
AU (1) AU2004286933B2 (pt)
BR (1) BRPI0414918A (pt)
CA (1) CA2540704A1 (pt)
DE (1) DE602004020364D1 (pt)
ES (1) ES2323178T3 (pt)
HR (1) HRP20060126A2 (pt)
IL (1) IL174677A0 (pt)
NO (1) NO20061950L (pt)
NZ (1) NZ546259A (pt)
PT (1) PT1673348E (pt)
RU (1) RU2006110561A (pt)
TW (1) TW200526637A (pt)
WO (1) WO2005044807A2 (pt)
ZA (1) ZA200603411B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
MXPA06011021A (es) 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
CA2609716C (en) 2005-05-26 2014-10-14 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
EP2308840A1 (en) * 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
CA2627722A1 (en) † 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20090281120A1 (en) * 2005-12-12 2009-11-12 Ono Pharmaceutical Co., Ltd Bicyclic heterocyclic compound
WO2007117400A2 (en) * 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
CN101460483B (zh) * 2006-03-31 2013-05-08 詹森药业有限公司 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪
EP2010177A2 (en) * 2006-04-10 2009-01-07 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
EA019143B1 (ru) 2008-06-12 2014-01-30 Янссен Фармацевтика Нв Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
CN103319459A (zh) 2008-06-30 2013-09-25 詹森药业有限公司 用于制备苯并咪唑-2-基嘧啶衍生物的方法
EP2350032B1 (en) * 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazole compounds and methods of use
WO2010036908A1 (en) * 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Use of benzoxazole compounds in the treatment of malaria
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
IT1395137B1 (it) * 2009-08-05 2012-09-05 Spider Biotech S R L Nuovi peptidi antipatogeni
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
DE102011122420B4 (de) 2011-12-24 2016-07-28 Volkswagen Aktiengesellschaft Verfahren zur Feststellung der Spannungsfreiheit in einem elektrischen Hochvolt-System und ein elektrisches Hochvolt-System
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP2671870A1 (en) * 2012-06-05 2013-12-11 Bioprojet Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
NZ710640A (en) 2013-03-06 2019-03-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
KR102779499B1 (ko) * 2018-05-22 2025-03-12 니혼노야쿠가부시키가이샤 벤즈이미다졸 화합물 또는 그의 염류 및 해당 화합물을 함유하는 농원예용 살충 살진드기제 그리고 그의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JP2000516611A (ja) * 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
ES2234318T3 (es) 1998-11-03 2005-06-16 ABBOTT GMBH & CO. KG 2-fenil-benzimidazoles sustituidos, su preparacion y uso.
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
AR045955A1 (es) * 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos

Also Published As

Publication number Publication date
US20090270611A1 (en) 2009-10-29
EP1673348B1 (en) 2009-04-01
WO2005044807A3 (en) 2005-08-11
ZA200603411B (en) 2007-07-25
US20090275748A1 (en) 2009-11-05
KR20060097024A (ko) 2006-09-13
CN1886380A (zh) 2006-12-27
WO2005044807A2 (en) 2005-05-19
US7723527B2 (en) 2010-05-25
DE602004020364D1 (de) 2009-05-14
AU2004286933B2 (en) 2010-11-18
RU2006110561A (ru) 2007-10-10
US20090270613A1 (en) 2009-10-29
US20090264647A1 (en) 2009-10-22
CN1886380B (zh) 2010-12-22
NZ546259A (en) 2009-05-31
US20090270366A1 (en) 2009-10-29
US20050070550A1 (en) 2005-03-31
US7705149B2 (en) 2010-04-27
IL174677A0 (en) 2006-08-20
TW200526637A (en) 2005-08-16
HRP20060126A2 (en) 2008-05-31
US7723526B2 (en) 2010-05-25
US20090264646A1 (en) 2009-10-22
PT1673348E (pt) 2009-05-11
US7705143B2 (en) 2010-04-27
US20090281307A1 (en) 2009-11-12
EP1673348A2 (en) 2006-06-28
US7662966B2 (en) 2010-02-16
CA2540704A1 (en) 2005-05-19
US20090247508A1 (en) 2009-10-01
NO20061950L (no) 2006-06-29
JP2007508011A (ja) 2007-04-05
ES2323178T3 (es) 2009-07-08
AR045955A1 (es) 2005-11-16
US7432378B2 (en) 2008-10-07
US7723359B2 (en) 2010-05-25
ATE427303T1 (de) 2009-04-15
AU2004286933A1 (en) 2005-05-19
US20090264645A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
BRPI0414918A (pt) compostos de benzoimidazola
CY1109413T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
BRPI0414533A (pt) composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
SE0101387D0 (sv) Novel compounds
DK0778731T3 (da) Ionenpolymerer indeholdende biologisk aktive anioner
BR9810342A (pt) Novos compostos imidazola substituìdos
PT892780E (pt) Analogos de m-amidino fenilo como inibidores do factor xa
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
ATE553086T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung der multipler medikamentenresistenz
BRPI0414313A (pt) inibidores de citocinas
BR9706934A (pt) Novos compostos de imidazol substituìdo
MEP36208A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
BRPI0814529B8 (pt) derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas de alfa2c para uso no tratamento de doenças do sistema nervoso periférico e central
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
ATE458497T1 (de) Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 235/18, C07D 401/04, C07D 401/12, C07D 401/14, C07D 403/12, A61K 31/454, A61K 31/4545, A61K 31/496, A61P 37/00

Ipc: C07D 235/18 (2011.01), C07D 401/12 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.